Client News
Roquefort Investments plc: Proposed Acquisition of Lyramid Pty LimitedRoquefort Investments plc (LSE:ROQ), the investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, is pleased to announce that further to the announcement of 29 September 2021, the Company has now entered into a conditional share sale and purchase agreement (the “Acquisition Agreement”) with Provelmare Holding S.A. (the “Seller”) pursuant to which Roquefort Investments has agreed to acquire the entire issued share capital of Lyramid Pty Limited (“Lyramid”) for an initial consideration of £1 million payable 50% in cash and 50% in shares (the “Acquisition”).
Lyramid has the exclusive worldwide licence to commercialise up to 37 patents related to Midkine-based therapies for the treatment of COVID-19 patients, cancer, autoimmune disorders and chronic inflammation (“Midkine-Based Therapies”).
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
CLIENT AREA
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.